What Individual Investors Don't See Until It's Too Late: The Arithmetic of a Headline Deal

On 30 July 2026, Korea's Financial Supervisory Service published its comprehensive plan to overhaul pharmaceutical and biotech disclosure. The reform is unusually specific about a single number: the total value of a technology-transfer agreement.

Under the new framework, a licensing deal can no longer be disclosed as one figure. Companies must break it into four lines — upfront payment, development milestones, approval and sales milestones, and royalties — and state the payment condition and character of each. The FSS was explicit about why: because only the total was published, milestones and royalties, which are payable solely on the satisfaction of conditions, were being read as amounts already secured at signing.

The reform reaches further back than that. At the IPO stage, the assumptions behind a valuation must now be set out in four standardised categories: expected market size, probability of clinical success, approval and review risk, and development period and cost. Expected market size must separate the total market from the actual addressable one. The probability of clinical success can no longer be an in-house estimate; it must rest on published literature or external statistics. A consolidated pipeline history table — covering completed, discontinued, and approved programmes, not only the live ones — becomes mandatory. Clinical result announcements must carry plain-language explanations of technical terms. And a press-release guideline now asks that material information reach the disclosure system first, with an internal approval step before distribution.

The gap the reform is aimed at

How large is the gap? Global benchmarks give a sense of scale. Across 516 biopharma licensing transactions announced in 2025 — more than $250 billion in headline value — upfront payments averaged about 7% of total deal value. Roughly 65% was tied to development and regulatory milestones, with commercial milestones accounting for a further 15–20% and tiered royalties running 10–20% of net sales. The pattern holds in the largest deals: GSK–Hengrui was structured as $500 million upfront against $12 billion-plus in total value across twelve candidates; BMS–BioNTech, $1.5 billion upfront against $11.1 billion.

None of this is concealment. Every one of those structures was negotiated openly and is standard practice. The asymmetry is not in the contract — it is in the compression. A deal that takes a decade to pay out is announced in a single line, and the line is a sum.

Reading it as a leading indicator

This is the terrain of momentum alignment. The index does not ask whether a company announced something large. It asks whether the announcement and the operating execution travel on the same clock — whether revenue growth and capital expenditure step forward together in the quarters that follow, or whether the headline stands by itself while the spending stays flat. A single quarter proves nothing. Four consecutive quarters of announcement without execution is a different object entirely.

That is why the reform matters beyond the pharmaceutical sector. Separating an upfront from a milestone does not change what a deal is worth. It changes when the market can tell — and by extension, who had that knowledge first.

The academic frame

Akerlof's 1970 analysis of markets with quality uncertainty established the base case: when sellers know more about quality than buyers and cannot credibly signal it, the market prices toward the average and good assets withdraw. Myers and Majluf (1984) sharpened this for corporate finance — when managers hold information investors do not, the timing and structure of announcements themselves become signals, and the information advantage is exercised through what is disclosed and when. A single-figure deal announcement is exactly the instrument their model predicts.

For the individual investor

The practical implication is narrow and usable. When you see a headline deal value, look for the payment schedule and the conditions attached to it. Then look at whether the company's spending moved in the quarters after the announcement. If the announcement is large and the execution is flat, you are not looking at a deal. You are looking at a disclosure.

Which raises the question worth carrying into next week: when a company announces something extraordinary, how many quarters do you give it before the absence of execution becomes the more informative fact?

This is a general structural observation based on public disclosures and reporting. It is not investment advice.

#RaymondsRisk #RelationalRisk #CorporateGovernance #InformationAsymmetry #BiotechLicensing #DisclosureReform